Moskovitz B, Nitecki S, Richter Levin D: Cancer of the prostate: is there a need for aggressive treatment? Urol Int 1987;42:49-52.Moskovitz B, Nitecki S, Richter-Levin D. Cancer of the prostate: is there a need for aggressive treatment? Urol Int 1987;42:49-52....
For the study, Clark and his colleagues looked at biopsies and other tests of more than 270 men with various stages of prostate cancer, as well as samples of prostates that have been removed, comparing urine tests with the patients' diagnosis. Dr. Anthony D'Amico, a professor of radiation ...
Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activation is broadly used and continually improved. However, a subset of patients eventually progresses...
Prostate cancer is the second leading cause of cancer deaths among men in the United States, and it disproportionally affects Black men, who are twice as likely to be diagnosed with and die of the disease. Catching this cancer in its early stages is key, as the five-year survival...
The role of dysregulation of mRNA alternative splicing (AS) in the development and progression of solid tumors remains to be defined. Here we describe the first comprehensive AS landscape in the spectrum of human prostate cancer (PCa) evolution. We find
In our study we reviewed 101 patients in stages T0b, T1 + T2, T3 (N0M0) who were treated by nonradical prostatectomy and no other treatment. The follow-up of these patients was 58 months. The actuarial 5- and 10-year survival according to stage was respectively: 91.30 and 64.62&#x...
Case 1: A 68-Year-Old Man with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (mCRPC) Siamak Daneshmand, MD, on next steps with TAR-200 in NMIBC What are the 5 stages of bladder health? Michael Cookson, MD, on potential future applications of PSMA-PETRelated...
To address this issue, we systematically prioritized and evaluated individual effects and complex interactions among 172 apoptotic SNPs in relation to PCA risk and aggressive disease (i.e., Gleason score ≥ 7 and tumor stages III/IV). Single and joint modifying effects on PCA outcomes among Europ...
Early diagnosis is pivotal to the treatment of all cancers, but some reveal their machinations far earlier than others. Prostate cancer is unfortunately one that might not show itself until in its later, more aggressive stages, so the search is on for tools that can pick it up earlier in th...
Figure 4 | (A): Subcellular localization and differential expression of MTA1 in cells representing different stages of PCa progression: RWPE1, ''normal'' immortalized prostate epithelial cells; LNCaP, androgen-responsive cells; Du145, androgen-resistant cells; PC3M, aggressive metastatic cells. (B...